NCT04157361 Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
| NCT ID | NCT04157361 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic |
| Condition | Bronchial Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2015-05-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2015-05-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.
Eligibility Criteria
Inclusion Criteria: * Children/adults with moderate or IgE mediated asthma * Children/adults with cystic fibrosis * Healthy control children/adults without lung disorders Exclusion Criteria: \-
Contact & Investigator
Petr Dzubak, MD, PhD.
STUDY DIRECTOR
The Institute of Molecular and Translational Medicine, Czech Republic
Frequently Asked Questions
Who can join the NCT04157361 clinical trial?
This trial is open to participants of all sexes, studying Bronchial Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04157361 currently recruiting?
Yes, NCT04157361 is actively recruiting participants. Contact the research team at petr.dzubak@upol.cz for enrollment information.
Where is the NCT04157361 trial being conducted?
This trial is being conducted at Olomouc, Czechia.
Who is sponsoring the NCT04157361 clinical trial?
NCT04157361 is sponsored by The Institute of Molecular and Translational Medicine, Czech Republic. The principal investigator is Petr Dzubak, MD, PhD. at The Institute of Molecular and Translational Medicine, Czech Republic. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.